Prestige Consumer Healthcare has acquired Pillar5, a manufacturer the company bought to gain greater control over its eye-care supply, according to remarks by Chairman, President and CEO Ron Lombardi on the company's fiscal second-quarter earnings call. The purchase price was not disclosed in the sources.
The deal was completed in the prior year relative to the earnings call, which was reported on November 8, 2026. Lombardi said Prestige had made site management changes at Pillar5 and that multiple regulatory inspections of the facility had concluded favorably.
The Pillar5 facility features in Prestige's discussion of its Clear Eyes brand, which has been constrained by production disruptions. Lombardi said production volatility began in late September and continued into October, and that with no safety stock available the disruption had an immediate effect on sales. Prestige now forecasts less than $20 million in full-year Clear Eyes sales, with limited improvement expected in the second half. Asked about the cause, Lombardi said there was "no one thing" impacting production and that the company was taking a broader look at the issues as they emerged.
Prestige reported fiscal second-quarter revenue of $336.3 million, up from $274.1 million a year earlier, growth of 22.7% driven by recent acquisitions. Excluding foreign currency effects and the Breathe Right and LaCorium acquisitions, revenue declined 1.6%, which management attributed to the timing of orders that benefited the first quarter.